RTP Mobile Logo
Ovarian Cancer Update, Issue 1, 2012
Released October 2012

Featuring interviews with Drs Robert A Burger and Tate Thigpen. (Audio Content)

CE Disclosures and Faculty Information


    Management of ovarian cancer (OC) includes optimal surgical debulking followed by postoperative chemotherapy and, in most cases, subsequent medical management when the disease recurs. Although many single-agent and combination chemotherapy regimens have been studied, only recently have antibody and small-molecule growth-inhibitory targeted agents been integrated into the OC research milieu. It is hoped that the results from these trials will lead to the emergence of new therapeutic agents and changes or enhancements in the indications for existing treatment strategies, ultimately improving the duration and quality of life for patients with metastatic OC. To bridge the gap between research and patient care, this issue of Ovarian Cancer Update features one-on-one discussions with leading gynecologic oncology investigators. By providing information on the latest research developments in the context of expert perspectives, this activity assists medical and gynecologic oncologists with the formulation of therapeutic strategies, which in turn facilitates optimal patient care.

    • Apply the results of emerging research with angiogenesis inhibition to the development of front-line and maintenance therapeutic strategies for patients with OC.
    • Develop an understanding of the unique mechanisms of action and emerging efficacy and toxicity profiles of investigational agents in OC to effectively prioritize clinical trial opportunities for appropriate patients.
    • Summarize available research data on the activity of PARP inhibitors in patients with advanced OC with or without BRCA mutations.
    • Determine the utility of CA125 serum levels in monitoring disease progression and making treatment recommendations for patients.
    • Communicate the benefits and risks of maintenance chemotherapy and/or biologic therapy to patients with advanced OC in first remission.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


    Research To Practice designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    This CME activity contains an audio component. To receive credit, the participant should listen to the audio MP3s, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located on our website at ResearchToPractice.com/OCU112/CME.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr BurgerConsulting Agreements: Eisai Inc, Endocyte Inc, Genentech BioOncology, Nektar, Sanofi; Honorarium: GlaxoSmithKline. Dr ThigpenAdvisory Committee: Amgen Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Genentech BioOncology, Janssen Biotech Inc; Speakers Bureau: Amgen Inc, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc.
    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.
    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc and Genentech BioOncology.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: October 2012
    Expiration date: October 2013

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio:
Ovarian Cancer Update, Issue 1, 2012
Released October 2012

Featuring interviews with Drs Robert A Burger and Tate Thigpen. (Audio Content)

Read print: